{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T17:24:35Z","timestamp":1783963475527,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Liver metastases from breast cancer (BCLM) are associated with aggressive disease and poor survival outcomes. Liver-directed locoregional therapies (LRT) based on radiation are limited by resistance and relapse. While liquid biopsy enables systemic monitoring, it provides limited insight into the tumor microenvironment and mechanisms of resistance. In this hypothesis-generating study, high-throughput plasma proteomics alongside digital spatial profiling of matched tumor tissues was employed to link systemic signals with local tumor biology, aiming to elucidate mechanisms underlying therapy response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Plasma and tissue samples were collected from BCLM (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200914) patients receiving LRT. High-throughput proteomic analysis (Olink Proteomics, Uppsala, Sweden) was run to detect and quantify circulating proteins in plasma. Matched tissue samples were obtained before LRT and analyzed using Digital Spatial Profiling (GeoMX, NanoString Technologies, Seattle, WA) to assess the protein expression within defined tissue compartments. Results were then correlated with clinical outcome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Systemic proteomic analysis showed significant high levels of CD8A, CX3CL1, FGF-21 before treatment in non-survivors suggesting a hyperactivated yet ineffective immune state. In contrast, survivors exhibited elevated plasma MMP1 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.035, AUC\u2009=\u20090.896) alongside reduced intratumoral levels. Spatial analysis did not identify significant differences in the distribution of immune cell signaling within the TME. However, compartment-specific profiling illuminated critical patterns: Ki-67 in immune stroma, not tumor cells, correlated with response, while fibronectin and \u03b1-SMA were abnormally enriched in tumor epithelial cells of non-survivors. These findings were consistent with a mesenchymal-like signature associated with poor survival, highlighting epithelial fibronectin as a candidate biomarker that warrants further investigation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Integrating plasma and spatial proteomics reveals key resistance mechanisms to LRT in BCLM with the opposing roles of MMP1 and fibronectin in blood versus tumor. Cancer-associated fibroblasts, linked to the epithelial compartment of the tumor, may represent potential targets for future investigation, particularly through MMP1 inhibition, potentially acting as adjuvants to radiation therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12935-026-04416-x","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T04:03:18Z","timestamp":1783915398000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrative plasma-to-spatial proteomics reveals fibroblast-associated signatures in liver metastatic breast cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Elif","family":"\u00d6cal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janik","family":"Riese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark P.","family":"K\u00fchnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Jonigk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidrun","family":"Hirner-Eppeneder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"\u00d6cal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Nahum","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Seidensticker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Wildgruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Alunni-Fabbroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"issue":"1","key":"4416_CR1","first-page":"10","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10\u201329.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4416_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41698-018-0047-0","volume":"2","author":"W Chen","year":"2018","unstructured":"Chen W, Hoffmann AD, Liu H, Liu X. Organotropism: new insights into molecular mechanisms of breast cancer metastasis. NPJ Precis Oncol. 2018;2(1):4.","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"4416_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41392-025-02148-4","volume":"10","author":"Y Li","year":"2025","unstructured":"Li Y, Liu F, Cai Q, Deng L, Ouyang Q, Zhang XH, et al. Invasion and metastasis in cancer: molecular insights and therapeutic targets. Signal Transduct Target Ther. 2025;10(1):57.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"4416_CR4","first-page":"438","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438\u201351.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"4416_CR5","doi-asserted-by":"publisher","first-page":"e0266522","DOI":"10.1371\/journal.pone.0266522","volume":"17","author":"M Moussa","year":"2022","unstructured":"Moussa M, Mwin D, Liao H, Atac MF, Markezana A, Galun E, et al. Myofibroblasts: A key promoter of tumorigenesis following radiofrequency tumor ablation. PLoS ONE. 2022;17(7):e0266522.","journal-title":"PLoS ONE"},{"issue":"6","key":"4416_CR6","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1097\/01.sla.0000246847.02058.1b","volume":"244","author":"R Adam","year":"2006","unstructured":"Adam R, Aloia T, Krissat J, Bralet MP, Paule B, Giacchetti S, et al. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg. 2006;244(6):897\u2013907.","journal-title":"Ann Surg"},{"key":"4416_CR7","doi-asserted-by":"publisher","first-page":"5937","DOI":"10.2147\/CMAR.S178395","volume":"10","author":"HY Zhao","year":"2018","unstructured":"Zhao HY, Gong Y, Ye FG, Ling H, Hu X. Incidence and prognostic factors of patients with synchronous liver metastases upon initial diagnosis of breast cancer: a population-based study. Cancer Manag Res. 2018;10:5937\u201350.","journal-title":"Cancer Manag Res"},{"issue":"12","key":"4416_CR8","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1093\/annonc\/mdx036","volume":"28","author":"F Cardoso","year":"2017","unstructured":"Cardoso F, Costa A, Senkus E, Aapro M, Andre F, Barrios CH, et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2017;28(12):3111.","journal-title":"Ann Oncol"},{"issue":"1","key":"4416_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10549-016-3974-x","volume":"160","author":"LG Eng","year":"2016","unstructured":"Eng LG, Dawood S, Sopik V, Haaland B, Tan PS, Bhoo-Pathy N, et al. Ten-year survival in women with primary stage IV breast cancer. Breast Cancer Res Treat. 2016;160(1):145\u201352.","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 3","key":"4416_CR10","doi-asserted-by":"publisher","first-page":"S1057","DOI":"10.1245\/s10434-015-4785-8","volume":"22","author":"A Ruiz","year":"2015","unstructured":"Ruiz A, Castro-Benitez C, Sebagh M, Giacchetti S, Castro-Santa E, Wicherts DA, et al. Repeat hepatectomy for breast cancer liver metastases. Ann Surg Oncol. 2015;22(Suppl 3):S1057-66.","journal-title":"Ann Surg Oncol"},{"key":"4416_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.887653","volume":"12","author":"C Liu","year":"2022","unstructured":"Liu C, Tadros G, Smith Q, Martinez L, Jeffries J, Yu Z, et al. Selective internal radiation therapy of metastatic breast cancer to the liver: a meta-analysis. Front Oncol. 2022;12:887653.","journal-title":"Front Oncol"},{"issue":"2","key":"4416_CR12","doi-asserted-by":"publisher","first-page":"e2329454","DOI":"10.2214\/AJR.23.29454","volume":"222","author":"AR Deipolyi","year":"2024","unstructured":"Deipolyi AR, Ward RC, Riaz A, Vogl TJ, Simmons RM, Pieper CC, et al. Locoregional therapies for primary and metastatic breast cancer: AJR expert panel narrative review. AJR Am J Roentgenol. 2024;222(2):e2329454.","journal-title":"AJR Am J Roentgenol"},{"issue":"6","key":"4416_CR13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.brachy.2019.08.003","volume":"18","author":"P Hass","year":"2019","unstructured":"Hass P, Mohnike K, Kropf S, Brunner TB, Walke M, Albers D, et al. Comparative analysis between interstitial brachytherapy and stereotactic body irradiation for local ablation in liver malignancies. Brachytherapy. 2019;18(6):823\u20138.","journal-title":"Brachytherapy"},{"key":"4416_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246250","author":"F Walter","year":"2021","unstructured":"Walter F, Rottler M, Nierer L, Landry G, Well J, Rogowski P, et al. Interstitial high-dose-rate brachytherapy of liver metastases in oligometastatic patients. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13246250.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"4416_CR15","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andre F, Barrios CH, Cortes J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475\u201395.","journal-title":"Ann Oncol"},{"key":"4416_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010871","author":"M Liu","year":"2025","unstructured":"Liu M, Qian M, Sun W, Sun X, Sun Y, Yu M, et al. Immunosuppressive microenvironment of liver restrains chemotherapeutic efficacy in triple-negative breast cancer. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2024-010871.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"4416_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10549-024-07295-w","volume":"206","author":"R Hsu","year":"2024","unstructured":"Hsu R, Al-Zubeidy B, Flores D, Nazarian A, Baugh A, Gonzalez E, et al. Evaluation of markers of immunity in different metastatic immune microenvironments suggests more suppression within breast to liver metastases in breast cancer. Breast Cancer Res Treat. 2024;206(2):245\u201359.","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"4416_CR18","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/j.ccell.2025.06.007","volume":"43","author":"D He","year":"2025","unstructured":"He D, Wu Q, Tian P, Liu Y, Jia Z, Li Z, et al. Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps. Cancer Cell. 2025;43(9):1622\u2013e367.","journal-title":"Cancer Cell"},{"issue":"24","key":"4416_CR19","doi-asserted-by":"publisher","first-page":"4497","DOI":"10.1158\/0008-5472.CAN-22-1902","volume":"82","author":"IE Elkholi","year":"2022","unstructured":"Elkholi IE, Lalonde A, Park M, Cote JF. Breast Cancer Metastatic Dormancy and Relapse: An Enigma of Microenvironment(s). Cancer Res. 2022;82(24):4497\u2013510.","journal-title":"Cancer Res"},{"issue":"1","key":"4416_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131.","journal-title":"Mol Cancer"},{"key":"4416_CR21","doi-asserted-by":"crossref","unstructured":"Ciurescu S, Buciu V, Serban D, Borozan F, Tomescu L, Cobec IM et al. Role of Cytokines in Breast Cancer: A Systematic Review and Meta-Analysis. Biomedicines. 2025;13(9).","DOI":"10.3390\/biomedicines13092203"},{"issue":"17","key":"4416_CR22","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1158\/1078-0432.CCR-22-0569","volume":"28","author":"TWH Shuen","year":"2022","unstructured":"Shuen TWH, Alunni-Fabbroni M, Ocal E, Malfertheiner P, Wildgruber M, Schinner R, et al. Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial. Clin Cancer Res. 2022;28(17):3890\u2013901.","journal-title":"Clin Cancer Res"},{"key":"4416_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.890410","volume":"12","author":"S Hernandez","year":"2022","unstructured":"Hernandez S, Lazcano R, Serrano A, Powell S, Kostousov L, Mehta J, et al. Challenges and opportunities for immunoprofiling using a spatial high-plex technology: the NanoString GeoMx((R)) digital spatial profiler. Front Oncol. 2022;12:890410.","journal-title":"Front Oncol"},{"issue":"8","key":"4416_CR24","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1016\/S1470-2045(23)00286-3","volume":"24","author":"D Pasquier","year":"2023","unstructured":"Pasquier D, Bidaut L, Oprea-Lager DE, deSouza NM, Krug D, Collette L, et al. Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups. Lancet Oncol. 2023;24(8):e331\u201343.","journal-title":"Lancet Oncol"},{"issue":"11","key":"4416_CR25","doi-asserted-by":"publisher","first-page":"e112731","DOI":"10.1371\/journal.pone.0112731","volume":"9","author":"M Seidensticker","year":"2014","unstructured":"Seidensticker M, Seidensticker R, Damm R, Mohnike K, Pech M, Sangro B, et al. Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity. PLoS ONE. 2014;9(11):e112731.","journal-title":"PLoS ONE"},{"issue":"12","key":"4416_CR26","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1038\/s41591-024-03269-z","volume":"30","author":"B Xu","year":"2024","unstructured":"Xu B, Wang S, Yan M, Sohn J, Li W, Tang J, et al. Sacituzumab govitecan in HR(+)HER2(-) metastatic breast cancer: the randomized phase 3 EVER-132-002 trial. Nat Med. 2024;30(12):3709\u201316.","journal-title":"Nat Med"},{"key":"4416_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071691","author":"F Galiandro","year":"2022","unstructured":"Galiandro F, Agnes S, Moschetta G, Orlandi A, Clarke G, Bria E, et al. Prognostic factors in patients with breast cancer liver metastases undergoing liver resection: systematic review and meta-analysis. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14071691.","journal-title":"Cancers (Basel)"},{"key":"4416_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17233823","author":"G Narayanan","year":"2025","unstructured":"Narayanan G, Ruiz EM, Dijkstra M, Gentile NT, Donahue D, Gandhi RT, et al. Clinical efficacy of percutaneous image-guided ablation in breast cancer metastases to the liver. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17233823.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4416_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1148\/radiology.220.1.r01jl01145","volume":"220","author":"T Livraghi","year":"2001","unstructured":"Livraghi T, Goldberg SN, Solbiati L, Meloni F, Ierace T, Gazelle GS. Percutaneous radio-frequency ablation of liver metastases from breast cancer: initial experience in 24 patients. Radiology. 2001;220(1):145\u20139.","journal-title":"Radiology"},{"issue":"1 Pt 1","key":"4416_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jvir.2006.10.014","volume":"18","author":"G Gunabushanam","year":"2007","unstructured":"Gunabushanam G, Sharma S, Thulkar S, Srivastava DN, Rath GK, Julka PK, et al. Radiofrequency ablation of liver metastases from breast cancer: results in 14 patients. J Vasc Interv Radiol. 2007;18(1 Pt 1):67\u201372.","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"4416_CR31","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson E, Lundberg M, Holmquist G, Bjorkesten J, Thorsen SB, Ekman D, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE. 2014;9(4):e95192.","journal-title":"PLoS ONE"},{"issue":"1","key":"4416_CR32","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1021\/acs.jproteome.0c00641","volume":"20","author":"A Petrera","year":"2021","unstructured":"Petrera A, von Toerne C, Behler J, Huth C, Thorand B, Hilgendorff A, et al. Multiplatform approach for plasma proteomics: complementarity of Olink proximity extension assay technology to mass spectrometry-based protein profiling. J Proteome Res. 2021;20(1):751\u201362.","journal-title":"J Proteome Res"},{"issue":"8","key":"4416_CR33","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.jtho.2022.04.009","volume":"17","author":"M Moutafi","year":"2022","unstructured":"Moutafi M, Martinez-Morilla S, Divakar P, Vathiotis I, Gavrielatou N, Aung TN, et al. Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling. J Thorac Oncol. 2022;17(8):991\u20131001.","journal-title":"J Thorac Oncol"},{"issue":"17","key":"4416_CR34","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1200\/JCO.2002.02.026","volume":"20","author":"SE Singletary","year":"2002","unstructured":"Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20(17):3628\u201336.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4416_CR35","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019;20(3):326\u201336.","journal-title":"Nat Immunol"},{"key":"4416_CR36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.semcancer.2020.06.003","volume":"71","author":"AT Ciner","year":"2021","unstructured":"Ciner AT, Jones K, Muschel RJ, Brodt P. The unique immune microenvironment of liver metastases: challenges and opportunities. Semin Cancer Biol. 2021;71:143\u201356.","journal-title":"Semin Cancer Biol"},{"key":"4416_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.812210","volume":"12","author":"K He","year":"2021","unstructured":"He K, Barsoumian HB, Bertolet G, Verma V, Leuschner C, Koay EJ, et al. Novel use of low-dose radiotherapy to modulate the tumor microenvironment of liver metastases. Front Immunol. 2021;12:812210.","journal-title":"Front Immunol"},{"key":"4416_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094679","author":"D Szukiewicz","year":"2024","unstructured":"Szukiewicz D. CX3CL1 (fractalkine)-CX3CR1 axis in inflammation-induced angiogenesis and tumorigenesis. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25094679.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4416_CR39","doi-asserted-by":"publisher","first-page":"E292","DOI":"10.1152\/ajpendo.00101.2017","volume":"313","author":"T Xie","year":"2017","unstructured":"Xie T, Leung PS. Fibroblast growth factor 21: a regulator of metabolic disease and health span. Am J Physiol Endocrinol Metab. 2017;313(3):E292\u2013302.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"4416_CR40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41420-024-01833-7","volume":"10","author":"Y Chen","year":"2024","unstructured":"Chen Y, Huang L, Gan RH, Yuan S, Lan T, Zheng D, et al. IL-8 activates fibroblasts to promote the invasion of HNSCC cells via STAT3-MMP1. Cell Death Discov. 2024;10(1):65.","journal-title":"Cell Death Discov"},{"issue":"3","key":"4416_CR41","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174\u201386.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4416_CR42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physrev.00048.2019","volume":"101","author":"G Biffi","year":"2021","unstructured":"Biffi G, Tuveson DA. Diversity and biology of cancer-associated fibroblasts. Physiol Rev. 2021;101(1):147\u201376.","journal-title":"Physiol Rev"},{"issue":"1","key":"4416_CR43","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","volume":"141","author":"K Kessenbrock","year":"2010","unstructured":"Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52\u201367.","journal-title":"Cell"},{"key":"4416_CR44","doi-asserted-by":"crossref","unstructured":"Aoudjehane L, Pissaia A Jr., Scatton O, Podevin P, Massault PP, Chouzenoux S, et al. Interleukin-4 induces the activation and collagen production of cultured human intrahepatic fibroblasts via the STAT-6 pathway. Lab Invest. 2008;88(9):973\u201385.","DOI":"10.1038\/labinvest.2008.61"},{"issue":"3","key":"4416_CR45","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ccell.2023.02.015","volume":"41","author":"G Caligiuri","year":"2023","unstructured":"Caligiuri G, Tuveson DA. Activated fibroblasts in cancer: perspectives and challenges. Cancer Cell. 2023;41(3):434\u201349.","journal-title":"Cancer Cell"},{"key":"4416_CR46","doi-asserted-by":"publisher","first-page":"1352632","DOI":"10.3389\/fimmu.2024.1352632","volume":"15","author":"A Kraxner","year":"2024","unstructured":"Kraxner A, Braun F, Cheng WY, Yang TO, Pipaliya S, Canamero M, et al. Investigating the complex interplay between fibroblast activation protein alpha-positive cancer associated fibroblasts and the tumor microenvironment in the context of cancer immunotherapy. Front Immunol. 2024;15:1352632.","journal-title":"Front Immunol"},{"issue":"10","key":"4416_CR47","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41423-025-01298-3","volume":"22","author":"Y Nusse","year":"2025","unstructured":"Nusse Y, Kubes P. Liver macrophages: development, dynamics, and functions. Cell Mol Immunol. 2025;22(10):1178\u201389.","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"4416_CR48","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1148\/radiol.15141918","volume":"276","author":"N Rozenblum","year":"2015","unstructured":"Rozenblum N, Zeira E, Bulvik B, Gourevitch S, Yotvat H, Galun E, et al. Radiofrequency Ablation: Inflammatory Changes in the Periablative Zone Can Induce Global Organ Effects, including Liver Regeneration. Radiology. 2015;276(2):416\u201325.","journal-title":"Radiology"},{"issue":"7","key":"4416_CR49","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","volume":"55","author":"D Yang","year":"2023","unstructured":"Yang D, Liu J, Qian H, Zhuang Q. Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp Mol Med. 2023;55(7):1322\u201332.","journal-title":"Exp Mol Med"},{"issue":"12","key":"4416_CR50","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/nrd4390","volume":"13","author":"RE Vandenbroucke","year":"2014","unstructured":"Vandenbroucke RE, Libert C. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discovery. 2014;13(12):904\u201327.","journal-title":"Nat Rev Drug Discovery"},{"key":"4416_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28145567","author":"S Almutairi","year":"2013","unstructured":"Almutairi S, Kalloush HM, Manoon NA, Bardaweel SK. Matrix metalloproteinases inhibitors in cancer treatment: an updated review (2013\u20132023). Molecules. 2013. https:\/\/doi.org\/10.3390\/molecules28145567.","journal-title":"Molecules"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04416-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04416-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04416-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T17:01:49Z","timestamp":1783962109000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-026-04416-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4416"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04416-x","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study represents a sub-analysis of all available liver metastatic breast cancer patients treated with radiation-based therapy at the Department of Radiology, LMU Hospital (German Clinical Trials Register-ID: DRKS00009744, DRKS00009916, DRKS00010587, DRKS00034084). All study protocols were conducted in accordance with the Declaration of Helsinki. Before entering the study, all patients were fully informed by the treating physician of the scope and goals of the trial, had given written informed consent, and were willing to comply with the study protocol.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"258"}}